drugset / Trial / NCT02799069

Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy

NCT02799069

Phase 3 Completed 571 enrolled Biofrontera Bioscience GmbH Accovion GmbH · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

The aim of the study is to evaluate the non-inferiority of BF-200 ALA (Ameluz) in the treatment of actinic keratosis (AK) with photodynamic therapy (PDT) compared to Metvix.

Timeline

Start
2008-04
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aminolevulinic Acid Diagnostic / imaging agent 78 unknown Topical
Comparator methyl aminolevulinate Small molecule 160 unknown Topical

Indications